Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13359115 | 1.00 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3RIPK1CYP1A2 | |
| SCHEMBL19361123 | 1.00 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3RIPK1CYP1A2 | |
| SCHEMBL9746668 | 0.88 | RIPK1 (0.43) | RIPK1ESR1ESR2TAAR1 | |
| SCHEMBL9015763 | 0.84 | SLC2A1 (0.39) | — | |
| SCHEMBL3455850 | 0.81 | ALDH1A1 (0.44) | CYP1A2CYP2D6 | |
| SCHEMBL13049653 | 0.81 | ALDH1A1 (0.44) | CYP1A2CYP2D6 | |
| SCHEMBL11570597 | 0.80 | TRPA1 (0.46) | RIPK1CYP1A2CYP2D6APEX1PMP22 | |
| SCHEMBL27146447 | 0.80 | TAAR1 (0.40) | RIPK1CYP1A2CYP2D6APEX1PMP22 | |
| SCHEMBL11655780 | 0.80 | RIPK1 (0.35) | RIPK1CYP1A2CYP2D6APEX1PMP22 | |
| SCHEMBL10446001 | 0.79 | CA12 (0.47) | SLC6A2SLC6A4SLC6A3RIPK1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019039198-A1 | METHOD FOR CONTROLLING BACTERIAL DISEASE DAMAGE OF PLANT USING PHENYLACETONITRILE DERIVATIVE | アグロカネショウ株式会社 | 2019-02-28 | — | — | WO | disclosed |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | SLC6A2 46/4885SLC6A4 65/4885SLC6A3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.